http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020178451-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_914ce1e64249e3dc0af1b375f3920f5d |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate | 2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72f1f61323db9bb7313fa19319baa6ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daf9636508ae9aec600076f5dc86a8a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a4e7724de9c316a33302a53b800a52c |
publicationDate | 2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2020178451-A1 |
titleOfInvention | Macrophage markers in cancer |
abstract | The present invention relates to the diagnosis, prognosis, prediction and/or treatment of cancer, for example breast cancer, lung cancer or colon cancer. The present invention provides methods of diagnosing and/or prognosing cancer, predicting efficacy of treatment for cancer, assessing outcome of treatment for cancer, assessing likelihood of metastasis and/or assessing recurrence of cancer, the methods comprising a) analyzing a biological sample obtained from a subject to determine the presence of one or more target molecules representative of expression of SIGLEC1 and/or CCL8; and b) comparing the expression level of SIGLEC1 and/or CCL8 determined in (a) with one or more reference values, wherein whether there is a difference in the expression of SIGLEC1 and/or CCL8 in the sample from the subject or not compared to the one or more reference values is indicative of a clinical indication. The invention further provides related methods for treatment of cancer, kits and assay devices for use in the methods, and methods for identifying molecules for use in treating cancer. |
priorityDate | 2019-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 618.